"The 120 subject phase 2 study is powered enough to produce statistically significant results."
What's your estimate of the necessary improvement in the primary endpoint ("time to sustained recovery through Day 29") that will show that brilacidin plus standard of care is statistically significantly superior to standard of care lone in a set of 120 patients?
My calculations suggest that even if brilacidin improves the the time to recovery by 1.65 days that will not be statistically significant in a 120 patient study.
FWIW I don't think that at the attenuated dose being tested even that degree of improvement will be shown.
However I do think that an exercise of drawing rings around the bullet holes in the brilacidin barn and then declaring it hit a different target (aka post hoc analyses) will suggest it's worth raising another few million to do a Phase IIb study.
At which point Kips Bay, Aspire and Mr. Ehrlich rub their hands in anticpation of futher riches for them to come (not for IPIX shareholders, natch, but they've demonstrated time and time again that those folk believe the jam tomorrow story, so who cares about those suckers?).
News 
Market Data 
Discover 
